Gene therapeutic approach for inhibiting hepatitis C virus replication using a recombinant protein that controls interferon expression

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 12, 2010, Pages 5048-5056

  Joo, Chul Hyun ^a   Lee, Uk ^a   Nam, Young Ran ^a   Jung, Jae U ^b   Lee, Heuiran ^a   Cho, Young Keol ^a   Kim, Yoo Kyum ^a  

^a University of Ulsan College of Medicine   (South Korea)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; INTERFERON; PROTEASE ACTIVATED TRANSCRIPTION TO INHIBIT HEPATITIS C; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ARTICLE; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; VIRUS REPLICATION;

ADENOVIRIDAE; CELL LINE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; GENE THERAPY; GENETIC VECTORS; HELA CELLS; HEPACIVIRUS; HEPATITIS C; HUMANS; IMMUNOBLOTTING; INTERFERONS; MODELS, BIOLOGICAL; RECOMBINANT PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; VIRUS REPLICATION;

EID: 78649653349     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00682-10     Document Type: Article

References (42)

1. Amako, Y., K. Tsukiyama-Kohara, A. Katsume, Y. Hirata, S. Sekiguchi, Y. Tobita, Y. Hayashi, T. Hishima, N. Funata, H. Yonekawa, and M. Kohara. 2010. Pathogenesis of hepatitis C virus infection in Tupaia belangeri. J. Virol. 84:303-311.
2. Baldo, V., T. Baldovin, R. Trivello, and A. Floreani. 2008. Epidemiology of HCV infection. Curr. Pharm. Des. 14:1646-1654.
3. Bigger, C. B., K. M. Brasky, and R. E. Lanford. 2001. DNA microarray analysis of chimpanzee liver during acute resolving hepatitis C virus infection. J. Virol. 75:7059-7066.
4. Bigger, C. B., B. Guerra, K. M. Brasky, G. Hubbard, M. R. Beard, B. A. Luxon, S. M. Lemon, and R. E. Lanford. 2004. Intrahepatic gene expression during chronic hepatitis C virus infection in chimpanzees. J. Virol. 78:13779-13792.
5. Bramson, J. L., K. Dayball, J. R. Hall, J. B. Millar, M. Miller, Y. H. Wan, R. Lin, and J. Hiscott. 2003. Super-activated interferon-regulatory factors can enhance plasmid immunization. Vaccine 21:1363-1370.
6. Butt, A. A., X. Wang, and C. G. Moore. 2009. Effect of hepatitis C virus and its treatment on survival. Hepatology 50:387-392.
7. Caillaud, A., A. Prakash, E. Smith, A. Masumi, A. G. Hovanessian, D. E. Levy, and I. Marie. 2002. Acetylation of interferon regulatory factor-7 by p300/CREB-binding protein (CBP)-associated factor (PCAF) impairs its DNA binding. J. Biol. Chem. 277:49417-49421.
8. Daya, S., and K. I. Berns. 2008. Gene therapy using adeno-associated virus vectors. Clin. Microbiol. Rev. 21:583-593.
9. Dubuisson, J. 2007. Hepatitis C virus proteins. World J. Gastroenterol. 13:2406-2415.
10. Gómez, J., M. Martell, J. Quer, B. Cabot, and J. I. Esteban. 1999. Hepatitis C viral quasispecies. J. Viral Hepat. 6:3-16.
11. Grimm, D., and J. A. Kleinschmidt. 1999. Progress in adeno-associated virus type 2 vector production: promises and prospects for clinical use. Hum. Gene Ther. 10:2445-2450.
12. Honda, K., H. Yanai, H. Negishi, M. Asagiri, M. Sato, T. Mizutani, N. Shimada, Y. Ohba, A. Takaoka, N. Yoshida, and T. Taniguchi. 2005. IRF-7 is the master regulator of type-I interferon-dependent immune responses. Nature 434:772-777.
13. Jones, C. T., M. T. Catanese, L. M. Law, S. R. Khetani, A. J. Syder, A. Ploss, T. S. Oh, J. W. Schoggins, M. R. MacDonald, S. N. Bhatia, and C. M. Rice. 2010. Real-time imaging of hepatitis C virus infection using a fluorescent cell-based reporter system. Nat. Biotechnol. 28:167-171.
14. Kawai, T., and S. Akira. 2006. Innate immune recognition of viral infection. Nat. Immunol. 7:131-137.
15. Kim, S. J., W. I. Lee, H. Heo, O. Shin, Y. K. Kwon, and H. Lee. 2007. Stable gene expression by self-complementary adeno-associated viruses in human MSCs. Biochem. Biophys. Res. Commun. 360:573-579.
16. Kim, S. J., W. I. Lee, Y. S. Lee, D. H. Kim, J. W. Chang, S. W. Kim, and H. Lee. 2009. Effective relief of neuropathic pain by adeno-associated virus-mediated expression of a small hairpin RNA against GTP cyclohydrolase 1. Mol. Pain 5:67.
17. König, R., S. Stertz, Y. Zhou, A. Inoue, H. H. Hoffmann, S. Bhattacharyya, J. G. Alamares, D. M. Tscherne, M. B. Ortigoza, Y. Liang, Q. Gao, S. E. Andrews, S. Bandyopadhyay, P. De Jesus, B. P. Tu, L. Pache, C. Shih, A. Orth, G. Bonamy, L. Miraglia, T. Ideker, A. Garcia-Sastre, J. A. Young, P. Palese, M. L. Shaw, and S. K. Chanda. 2010. Human host factors required for influenza virus replication. Nature 463:813-817.
18. Kronenberger, B., C. Welsch, N. Forestier, and S. Zeuzem. 2008. Novel hepatitis C drugs in current trials. Clin. Liver Dis. 12:529-555.
19. Lanford, R. E., M. J. Evans, V. Lohmann, B. Lindenbach, M. Gale, Jr., B. Rehermann, K. M. Chang, and S. M. Lemon. 2009. The accelerating pace of HCV research: a summary of the 15th International Symposium on Hepatitis C Virus and Related Viruses. Gastroenterology 136:9-16.
20. Levy, D. E., I. Marie, E. Smith, and A. Prakash. 2002. Enhancement and diversification of IFN induction by IRF-7-mediated positive feedback. J. Interferon Cytokine Res. 22:87-93.
21. Liang, Y., H. Ishida, O. Lenz, T. I. Lin, O. Nyanguile, K. Simmen, R. B. Pyles, N. Bourne, M. Yi, K. Li, and S. M. Lemon. 2008. Antiviral suppression vs restoration of RIG-I signaling by hepatitis C protease and polymerase inhibitors. Gastroenterology 135:1710-1718.
22. Lin, R., P. Genin, Y. Mamane, and J. Hiscott. 2000. Selective DNA binding and association with the CREB binding protein coactivator contribute to differential activation of alpha/beta interferon genes by interferon regulatory factors 3 and 7. Mol. Cell. Biol. 20:6342-6353.
23. Lin, R., Y. Mamane, and J. Hiscott. 2000. Multiple regulatory domains control IRF-7 activity in response to virus infection. J. Biol. Chem. 275:34320-34327.
24. Lischka, P., O. Rosorius, E. Trommer, and T. Stamminger. 2001. A novel transferable nuclear export signal mediates CRM1-independent nucleocytoplasmic shuttling of the human cytomegalovirus transactivator protein pUL69. EMBO J. 20:7271-7283. (Pubitemid 34062318)
25. Major, M. E., B. Rehermann, and S. M. Feinstone. 2001. Hepatitis C viruses, p. 1127-1160. In D. M. Knipe and P. M. Howley (ed.), Fields Virology, Forth Edition ed., vol. 1. Lippincott Williams & Wilkins, Philadelphia, PA.
26. Manns, M. P., H. Wedemeyer, and M. Cornberg. 2006. Treating viral hepatitis C: efficacy, side effects, and complications. Gut 55:1350-1359.
27. Matsushita, T., S. Elliger, C. Elliger, G. Podsakoff, L. Villarreal, G. J. Kurtzman, Y. Iwaki, and P. Colosi. 1998. Adeno-associated virus vectors can be efficiently produced without helper virus. Gene Ther. 5:938-945. (Pubitemid 28371911)
28. Meylan, E., J. Curran, K. Hofmann, D. Moradpour, M. Binder, R. Bartenschlager, and J. Tschopp. 2005. Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus. Nature 437:1167-1172.
29. Mingozzi, F., and K. A. High. 2007. Immune responses to AAV in clinical trials. Curr. Gene Ther. 7:316-324.
30. Morin, P., J. Braganca, M. T. Bandu, R. Lin, J. Hiscott, J. Doly, and A. Civas. 2002. Preferential binding sites for interferon regulatory factors 3 and 7 involved in interferon-A gene transcription. J. Mol. Biol. 316:1009-1022.
31. Qi, B., Y. Huang, D. Rowe, and G. Halliday. 2007. VISA-a pass to innate immunity. Int. J. Biochem. Cell Biol. 39:287-291.
32. Rehermann, B., and M. Nascimbeni. 2005. Immunology of hepatitis B virus and hepatitis C virus infection. Nat. Rev. Immunol. 5:215-229.
33. Sasaki, S., R. R. Amara, W. S. Yeow, P. M. Pitha, and H. L. Robinson. 2002. Regulation of DNA-raised immune responses by cotransfected interferon regulatory factors. J. Virol. 76:6652-6659.
34. Seth, R. B., L. Sun, C. K. Ea, and Z. J. Chen. 2005. Identification and characterization of MAVS, a mitochondrial antiviral signaling protein that activates NF-kappaB and IRF 3. Cell 122:669-682.
35. Sharma, S., B. R. tenOever, N. Grandvaux, G. P. Zhou, R. Lin, and J. Hiscott. 2003. Triggering the interferon antiviral response through an IKK-related pathway. Science 300:1148-1151.
36. Sheehy, P., B. Mullan, I. Moreau, E. Kenny-Walsh, F. Shanahan, M. Scallan, and L. J. Fanning. 2007. In vitro replication models for the hepatitis C virus. J. Viral Hepat. 14:2-10.
37. Su, A. I., J. P. Pezacki, L. Wodicka, A. D. Brideau, L. Supekova, R. Thimme, S. Wieland, J. Bukh, R. H. Purcell, P. G. Schultz, and F. V. Chisari. 2002. Genomic analysis of the host response to hepatitis C virus infection. Proc. Natl. Acad. Sci. U. S. A. 99:15669-15674.
38. Thimme, R., J. Bukh, H. C. Spangenberg, S. Wieland, J. Pemberton, C. Steiger, S. Govindarajan, R. H. Purcell, and F. V. Chisari. 2002. Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease. Proc. Natl. Acad. Sci. U. S. A. 99:15661-15668.
39. Vandenberghe, L. H., J. M. Wilson, and G. Gao. 2009. Tailoring the AAV vector capsid for gene therapy. Gene Ther. 16:311-319.
40. Wakita, T., T. Pietschmann, T. Kato, T. Date, M. Miyamoto, Z. Zhao, K. Murthy, A. Habermann, H. G. Krausslich, M. Mizokami, R. Bartenschlager, and T. J. Liang. 2005. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat. Med. 11:791-796.
41. Xu, X., H. Chen, X. Cao, and K. Ben. 2007. Efficient infection of tree shrew (Tupaia belangeri) with hepatitis C virus grown in cell culture or from patient plasma. J. Gen. Virol. 88:2504-2512.
42. Zhao, X., Z. Y. Tang, B. Klumpp, G. Wolff-Vorbeck, H. Barth, S. Levy, F. von Weizsacker, H. E. Blum, and T. F. Baumert. 2002. Primary hepatocytes of Tupaia belangeri as a potential model for hepatitis C virus infection. J. Clin. Investig. 109:221-232.